Abstract P2-03-06: Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates

作者
E Johnson,Evin H. Gulbahce
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (4_Supplement): P2-03
标识
DOI:10.1158/1538-7445.sabcs17-p2-03-06
摘要

Abstract Introduction: A focused update of American Society of Clinical Oncology (ASCO) and College of American Pathologist's (CAP) guideline recommendations for HER2 testing in breast cancer (BrCa) was published in May, 2017 for public comment (http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution Folders/WebContent/pdf/her2-breast-summary-draft-recommendations-2017.pdf). The focused update for in situ hybridization (ISH) addresses following uncommon scenarios: 1) HER2/CEP17 ratio ≥ 2.0, and HER2 /cell <4.0; 2) HER2/CEP17 ratio <2.0 and HER2 /cell ≥6.0; 3) HER2/CEP17 <2.0 and HER2 /cell ≥4.0 and <6.0. The first two groups are currently reported as positive, the third as equivocal. It is recommended that immunohistochemistry (IHC) performed by the same lab for all these groups. If the IHC testing is 3+ or 0/1+ the final diagnosis will be reported as positive or negative respectively. If the reflex IHC is 2+, a recount of the original ISH area of carcinoma with IHC 2+ staining is recommended. The purpose of this study is to review the results of targeted FISH testing following IHC to predict the effects of proposed guidelines in a high volume national reference lab. Materials and methods: HER2 FISH tests performed on BrCa between 4/2015-5/2017 are included. Our lab offers HER2 testing by IHC (HercepTest™ Dako) and dual probe FISH (Dako IQ). Equivocal (2+) cases showing ≥10% weak or moderate circumferential membrane staining or intense but <10% circumferential staining are circled by a pathologist and reflexed to HER2 FISH with preferential counting performed in the circled areas. Equivocal FISH cases are re-tested with the alternate RAI1 probe (Agilent Technologies). FISH scoring is done manually by 2 people following 2013 ASCO/CAP guidelines with at least 20 cells counted in amplified and non-amplified cases and 40 cells counted in equivocal cases. Results: 2460 HER2 FISH test requests were received during the study period. 7 cases failed at initial testing and 13 cases failed at repeat testing of equivocal cases with reflex probe. 389 (16.2%) cases were amplified, 1686 (68.7%) non amplified, and 369 (15.0%) were equivocal with FDA approved probe set. 116 (32.6%) of equivocal cases re-tested with alternate probe were amplified increasing overall amplification rate to 21%. The table below shows cases that fall under 3 uncommon categories that are proposed for changes in draft guidelines. HER2/CEP17 RatioAverage HER2/CellNumber of Cases with IHC (Total Number)IHC n(result)Results per 2013 ASCO/CAP before Reflex ProbeResults per 2013 ASCO/CAP after Reflex ProbeProposed Guidelines≥ 2< 48 (28)7 (2+)POSITIVE-NEGATIVE 1 (1+) < 2≥ 69 (31)9 (2+)POSITIVE-NEGATIVE < 2≥ 4-698 (372)96 (2+)EQUIVOCAL32/98 (32.7%) POSITIVE1/98 (1%) POSITIVE 1 (3+) 1 (0) Conclusions: In our lab where all FISH tests with prior IHC are counted on targeted areas, all of the cases within the first two groups will be reclassified as negative. The use of reflex probe in equivocal cases is not recommended in the draft recommendations further decreasing positivity rates. Approximately 5% decrease is expected in HER2 FISH positivity rates following proposed recommendations in reference laboratory setting. Citation Format: Johnson E, Gulbahce E. Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-03-06.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lhm完成签到 ,获得积分10
刚刚
1秒前
无花果的应助被zy采纳,获得10
1秒前
xiaoX12138发布了新的文献求助10
1秒前
精明依云发布了新的文献求助10
2秒前
专一的弱完成签到,获得积分10
2秒前
2秒前
希望天下0贩的0的应助被Johnny采纳,获得10
2秒前
3秒前
Heven88发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
风中小丸子完成签到,获得积分10
3秒前
4秒前
可爱的函函的应助被paopao采纳,获得10
4秒前
4秒前
molihuakai的应助被ZZXX采纳,获得10
4秒前
Aurora完成签到 ,获得积分10
4秒前
小队昵称完成签到,获得积分10
5秒前
伽玛伽玛完成签到 ,获得积分10
6秒前
starcraftfan完成签到,获得积分10
7秒前
7秒前
xdy发布了新的文献求助10
7秒前
Walker完成签到,获得积分10
7秒前
星空完成签到,获得积分10
7秒前
贾贡献的应助被诚心的万宝路采纳,获得10
7秒前
rslysywd发布了新的文献求助10
7秒前
大气的杨完成签到 ,获得积分10
8秒前
雨文发布了新的文献求助10
8秒前
oooaaa发布了新的文献求助10
9秒前
精明依云发布了新的文献求助10
10秒前
大君完成签到,获得积分10
12秒前
百步穿小杨完成签到,获得积分10
12秒前
12秒前
12秒前
阿金发布了新的文献求助10
12秒前
13秒前
tuanzi完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621